瓦尔酸提高了威尼托克拉克斯在向急性髓性白血病的有效性
Renshi Kawakatsu1, Kenjiro Tadagaki1, Kenta Yamasaki1
1Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Diseases (Basel, Switzerland)
|January 24, 2025
概括
瓦尔酸 (VPA) 通过促进急性髓性白血病 (AML) 细胞的亡来增强venetoclax疗法. 这种组合为AML治疗提供了一个有希望的新策略,改善了患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性髓性白血病 (AML) 是一种具有有限治疗选择的侵袭性癌症.
- 作为Bcl-2抑制剂的Venetoclax显示出有效性,但在AML治疗方面存在局限性.
- 酸 (VPA) 是一种抗药,正在研究其抗癌特性.
研究的目的:
- 研究结合venetoclax与酸 (VPA) 的潜力,以增强AML的抗白血病作用.
- 确定这种组合对AML细胞活力,细胞周期和亡的影响.
主要方法:
- 急性髓性白血病 (AML) 细胞系单独使用venetoclax或与VPA结合治疗.
- 细胞活力通过试蓝排除进行评估.
- 使用流细胞计和RT-qPCR分析了细胞周期进展和与亡相关的蛋白质表达 (Bax,Bak,PARP).
主要成果:
- 个别治疗对AML细胞增殖的影响很小.
- 维内托克拉克斯和VPA的组合显著抑制了细胞生长,并诱导了大量的细胞死亡.
- 组合疗法上调了亲亡蛋白Bax和Bak,激活了卡斯帕斯 (通过PARP裂变表明),并导致了主要的亡细胞死亡.
结论:
- 瓦尔酸 (VPA) 在AML细胞系中增强了venetoclax诱导的亡.
- 这项研究强调了VPA在增强venetoclax疗效方面的新作用.
- 这些发现表明,结合venetoclax和VPA用于AML管理的有希望的治疗策略.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
224
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
224
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
464
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
464
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
219
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
219


